Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Acne Treatment Labels Should Add Sensitivity Test Direction – FDA

This article was originally published in The Tan Sheet

Executive Summary

OTC topical acne drug product manufacturers have an option to add label directions for sensitivity testing for new users of their products, “to reduce the risk of serious hypersensitivity reactions,” the FDA says.

You may also be interested in...



FDA Evaluates Topical Acne Ingredients After Adverse Event Report Jump

A recent uptick in the number of adverse events reported for benzoyl peroxide and salicylic acid products has pushed the regulatory agency to take a closer look at the potential for safety issues.

NAC’s Longevity In US Dietary Supplement Market Swings On Comments As NDI Notifications

FDA ODSP details “data, research results, and other information” it needs on NAC that could sway proposing a rulemaking to allow its continued use in supplements. One detail missing is what the agency’s asking for are NDI notifications for NAC.

P&G Among US Firms Asked To Explain How, Why Supply Chain Problems Cause Consumer Hardships

Procter & Gamble and Amazon are among nine companies FTC ordered to provide detailed information to help the agency identify causes behind ongoing supply chain disruptions. Chairwoman Khan says the information should “shed light on market conditions and business practices that may have worsened these disruptions.”

Topics

Related Companies

UsernamePublicRestriction

Register

PS106994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel